Recent Updates
Recently added Catalysts
BDSX Positive Sentiment

Biodesix to Participate in Upcoming Investor Conferences

Key Takeaway: Biodesix, Inc. will participate in three upcoming investor conferences in New York, including the Lake Street Capital Markets' 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Additionally, Biodesix will present a panel discussion on MRD monitoring in solid tumors at the Roth Healthcare Opportunities Conference. These events underscore Biodesix's commitment to advancing diagnostic solutions.
Price reaction · baseline $27.16 (2026-09-02 close) · hit pre-market · clean, no other BDSX news in the window
day 0 close · peak
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Biodesix is actively engaging with investors through multiple conferences.
  • The company is showcasing its leadership in diagnostic solutions.
  • Presentations at major conferences highlight Biodesix's innovative approaches.

Full Press Release Details

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:

Lake Street Capital Markets’ 10 th Annual Best Ideas Growth (BIG10) Conference 1x1 meetings only Date: Thursday, September 10 Location: New York, NY

H.C. Wainwright 28 th Annual Global Investment Conference 1x1 meetings only Date: Tuesday, September 15 Location: New York

5 th Annual Roth Healthcare Opportunities Conference Panel and 1x1 meetings Panel Title: The Rise of MRD Monitoring in Solid Tumors, and Where it Goes Next Biodesix Presenter: Gary Pestano, Ph.D., Chief Scientific Officer Panel Date and Time: Tuesday, September 29, 2:00 PM ET Location: New York

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts: Media: Natalie St. Denis, Director Corporate Communications natalie.stdenis@biodesix.com (720) 925-9285

Investors: Chris Brinzey, Partner, ICR chris.brinzey@icrhealthcare.com (339) 970-2843

Frequently Asked Questions

Which investor conferences will Biodesix attend?

Biodesix will attend the Lake Street Capital Markets, H.C. Wainwright, and Roth Healthcare Opportunities Conferences.

Who will represent Biodesix at the Roth Conference?

Gary Pestano, Ph.D., Chief Scientific Officer, will represent Biodesix at the Roth Conference.

What is the focus of Biodesix's panel discussion?

The panel discussion will focus on MRD monitoring in solid tumors and future directions.

When is the Lake Street Capital Markets Conference?

The Lake Street Capital Markets Conference is scheduled for September 10.

Last updated: Sep 3, 2026